Jazz Pharmaceuticals Total Operating Expenses Over Time
| JAZZ Stock | USD 124.34 2.33 1.84% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Jazz Pharmaceuticals Performance and Jazz Pharmaceuticals Correlation. Jazz |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Jazz Pharmaceuticals. If investors know Jazz will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Jazz Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.597 | Earnings Share 7.06 | Revenue Per Share 64.039 | Quarterly Revenue Growth 0.085 | Return On Assets 0.0462 |
The market value of Jazz Pharmaceuticals PLC is measured differently than its book value, which is the value of Jazz that is recorded on the company's balance sheet. Investors also form their own opinion of Jazz Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Jazz Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Jazz Pharmaceuticals' market value can be influenced by many factors that don't directly affect Jazz Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Jazz Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Jazz Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Jazz Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Operating Expenses Analysis
Compare Jazz Pharmaceuticals PLC and related stocks such as Incyte, Alnylam Pharmaceuticals, and United Therapeutics Total Operating Expenses Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INCY | 1.6 M | 237.6 M | 295.8 M | 370.4 M | 513.3 M | 676.1 M | 885.1 M | 1.7 B | 1.6 B | 1.6 B | 2.8 B | 2.2 B | 2.6 B | 1.2 B | 679.9 M |
| ALNY | 4.2 M | 137.6 M | 131.2 M | 140.1 M | 234.8 M | 337.1 M | 471.7 M | 590 M | 887.8 M | 1.1 B | 1.2 B | 1.4 B | 1.7 B | 1.8 B | 1.9 B |
| UTHR | 13.4 M | 336.5 M | 375.1 M | 693.4 M | 623.8 M | 697.7 M | 464.4 M | 594.7 M | 623.7 M | 1.5 B | 781.6 M | 1 B | 809.9 M | 885.1 M | 469.6 M |
| RARE | 6.6 M | 6.6 M | 16 M | 32.3 M | 56.8 M | 147.7 M | 248.1 M | 331.6 M | 421.7 M | 518.9 M | 595 M | 717.1 M | 983.9 M | 958.2 M | 1 B |
| APLS | 4 M | 4 M | 4 M | 4 M | 11.3 M | 20.1 M | 27.3 M | 50.8 M | 127.9 M | 288 M | 439.3 M | 597.6 M | 664.4 M | 855.2 M | 898 M |
| BMRN | 14.8 M | 389.8 M | 519.1 M | 608.8 M | 781.7 M | 1 B | 1.1 B | 1.2 B | 1.3 B | 1.5 B | 1.4 B | 1.5 B | 1.6 B | 1.7 B | 1.8 B |
| EXEL | 17.6 M | 190 M | 160.7 M | 229.7 M | 239.9 M | 153.7 M | 212.1 M | 271.5 M | 388.6 M | 565.2 M | 841.2 M | 1.1 B | 1.4 B | 1.6 B | 1.7 B |
| HALO | 48.5 K | 75.7 M | 94.9 M | 129 M | 115.6 M | 133.3 M | 196.7 M | 204.5 M | 211.1 M | 218.1 M | 80 M | 86 M | 253.3 M | 299.3 M | 314.3 M |
| PCVX | 35.5 M | 35.5 M | 35.5 M | 35.5 M | 35.5 M | 35.5 M | 35.5 M | 35.5 M | 35.5 M | 53.9 M | 87.1 M | 102.1 M | 207.3 M | 468 M | 491.4 M |
| LQDA | 28.2 M | 28.2 M | 28.2 M | 28.2 M | 28.2 M | 28.2 M | 28.2 M | 35 M | 37.5 M | 54.1 M | 59.6 M | 43.6 M | 51.8 M | 88 M | 54.7 M |
| LEGN | 9.6 M | 9.6 M | 9.6 M | 9.6 M | 9.6 M | 9.6 M | 9.6 M | 9.6 M | 64.2 M | 192.6 M | 304.9 M | 462.8 M | 509.7 M | 583.1 M | 334.2 M |
| TECH | 5.8 M | 71.7 M | 74.8 M | 91.7 M | 160.3 M | 186.1 M | 252.8 M | 296 M | 326.8 M | 325.8 M | 395.6 M | 459.9 M | 470.9 M | 563 M | 591.2 M |
| INBX | 27.7 M | 27.7 M | 27.7 M | 27.7 M | 27.7 M | 27.7 M | 27.7 M | 27.7 M | 37 M | 52.8 M | 80.3 M | 83.7 M | 131.3 M | 219.8 M | 230.8 M |
| PTGX | 9.3 M | 9.3 M | 9.3 M | 9.3 M | 9.3 M | 14.8 M | 32.7 M | 58 M | 73.2 M | 80.8 M | 93.1 M | 153.2 M | 158 M | 153.7 M | 90.9 M |
| LRMR | 35.5 M | 35.5 M | 35.5 M | 35.5 M | 35.5 M | 73.7 M | 56.9 M | 53.7 M | 62.5 M | 23.2 M | 42.8 M | 50.5 M | 36.5 M | 41.8 M | 38.2 M |
| VRDN | 4.5 M | 4.5 M | 4.5 M | 2.3 M | 8 M | 11.3 M | 10.5 M | 30.5 M | 41.5 M | 46.4 M | 41.6 M | 82.7 M | 136.1 M | 254.8 M | 267.5 M |
| BPMC | 21 M | 21 M | 21 M | 21 M | 39.7 M | 63 M | 100.3 M | 172.7 M | 291.5 M | 427.8 M | 484.6 M | 804.1 M | 723.7 M | 722.9 M | 385.2 M |
| ASND | 14.1 M | 14.1 M | 14.1 M | 15.1 M | 26 M | 49.9 M | 77.5 M | 113.1 M | 165.3 M | 240.1 M | 337.6 M | 456 M | 600.9 M | 677.9 M | 711.8 M |
| ARGX | 6.2 M | 6.2 M | 15.5 M | 12.3 M | 17.6 M | 24.6 M | 38 M | 71.2 M | 118.2 M | 279.4 M | 561.8 M | 846 M | 1.1 B | 1.5 B | 1.6 B |
| DNLI | 16.7 M | 16.7 M | 16.7 M | 16.7 M | 16.7 M | 16.7 M | 87.4 M | 90.1 M | 175.5 M | 239.9 M | 272.9 M | 344.4 M | 449.2 M | 527.2 M | 269.3 M |
Jazz Pharmaceuticals PLC and related stocks such as Incyte, Alnylam Pharmaceuticals, and United Therapeutics Total Operating Expenses description
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.My Equities
My Current Equities and Potential Positions
| Jazz Pharmaceuticals PLC | JAZZ |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Ireland |
| Exchange | NASDAQ Exchange |
USD 124.34
Additional Tools for Jazz Stock Analysis
When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.